Glossary
- Absolute neutrophil count (ANC)
- Accelerated Approval
- Actionable target
- Active immunotherapy
- Active multiple myeloma
- Adaptive immunity
- Adhesion molecules
- Adjuvant
- Adriamycin (doxorubicin)
- Adverse event (AE)
- Albumin
- Alkeran®
- Allogeneic stem cell transplant
- Allograft
- Aloxi® (palonosetron)
- Alpha interferon
- Amyloid protein
- Amyloidosis
- Anemia
- Angiogenesis
- Anthracycline
- Antibody
- Antibody-drug conjugate (ADC)
- Antiemetic
- Antigen
- Antimicrobial
- Anzemet® (dolasetron)
- Apheresis
- Apoptosis
- Asthenia
- Autograft
- Autoimmune diseases
- Autologous
- Autologous stem cell transplant (ASCT)
- Autologous transplant
- B cell
- B-cell maturation antigen (BCMA)
- B lymphocyte
- Balloon kyphoplasty
- Basic fibroblast growth factor (bFGF)
- Bcl-2
- Bence-Jones protein
- Beta 2-microglobulin (ß2-microglobulin or ß2-M)
- Biaxin (clarithromycin)
- Bispecific antibody
- Bisphosphonate
- Blood urea nitrogen (BUN)
- Bone marrow
- Bone marrow aspiration
- Bone marrow biopsy
- Bone remodeling
- Bone resorption
- Bone (skeletal) survey
- C-reactive protein (CRP)
- Calcium
- Cancer vaccine
- Catheter
- CD34+
- Checkpoint inhibitor
- Chemistry profile
- Chemobrain
- Chemotherapy
- Chimeric antigen receptor T (CAR T) cell therapy
- Chromosomal abnormality
- Chromosomal deletion
- Chromosomal translocation
- Chromosome
- Chromosome analysis (cytogenetic testing)
- Clinical trial
- Colony-stimulating factor (CSF)
- Complete blood count (CBC)
- Complete remission
- Complete response (CR)
- Computed tomography (CT)
- Computerized axial tomography (CAT)
- Conditioning regimen
- Consolidation Therapy
- Conventional chemotherapy
- Cord blood transplant
- Corticosteroid
- Coumadin® (also known as warfarin)
- CR
- Creatinine
- Cryoglobulinemia
- Cryopreservation
- Cure
- Cutaneous T-cell lymphoma (CTCL)
- Cyclooxygenase-2 (COX-2)
- Cyclophosphamide
- Cyclosporine
- Cytogenetic testing
- Cytokine
- Cytoxan®
- Decadron® (dexamethasone)
- Deep vein thrombosis (DVT)
- Demographic
- Dendritic cell
- Dexamethasone
- Dialysis
- Disease-free survival
- DMSO
- DNA (deoxyribonucleic acid)
- Donor Lymphocyte Infusion (DLI)
- Doxil® (doxorubicin HCl liposome injection)
- Electrolytes
- Electrophoresis (EP)
- Emend® (aprepitant)
- Emerging therapy
- End point
- Endothelial cell
- Engraftment
- Enteritis
- Erythropoiesis
- Erythropoietin
- Esophagitis
- Event-free survival (EFS)
- Expanded access
- Extramedullary disease
- Farydak® (Panobinostat)
- Fast Track designation
- Febrile neutropenia
- Fibroblast growth factor 2 (FGF-2)
- Filgrastim
- Fluorescence in situ hybridization (FISH)
- Fluoroscope
- Formulation
- Free light chain (FLC)
- Frontline therapy
- Grade 1 Adverse Event (AE)
- Grade 2 AE
- Grade 3 AE
- Grade 4 AE
- Graft-versus-host disease (GVHD)
- Graft-versus-myeloma effect
- Granulocyte
- Granulocyte colony-stimulating factor (G-CSF)
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- Growth factors
- Hand-foot syndrome (HFS)
- Heavily pre-treated
- Heavy chain
- Hematocrit
- Hematologic
- Hematopoiesis
- Hematopoietic stem cells
- Hemoglobin
- Heparanase
- Heparin
- Hepatic impairment
- High-dose chemotherapy
- High risk myeloma
- Hypercalcemia
- Hypercalcemia of malignancy (HCM)
- Hyperviscosity syndrome
- Hypothyroidism
- Immune response
- Immune system
- Immunoelectrophoresis
- Immunofixation electrophoresis (IFE)
- Immunoglobulin
- Immunomodulatory agent
- Immunomodulatory drugs or IMiDs®
- Immunosuppressive drug
- Immunotherapy
- Induction therapy
- Infusion Reaction
- Institutional Review Board (IRB)
- Interferon (IFN)
- Interleukin 1 beta (IL-1b)
- Interleukin 10 (IL-10)
- Interleukin 12 (IL-12)
- Interleukin 2 (IL-2)
- Interleukin 4 (IL-4)
- Interleukin 5 (IL-5)
- Interleukin 6 (IL-6)
- Interleukin 8 (IL-8)
- Karyotyping
- Kepivance® (palifermin)
- Keratopathy
- Kyphoplasty
- Kyprolis™
- Kytril® (granisetron)
- Lactate dehydrogenase (LDH)
- Leukine® (sargramostim)
- Light chain
- Liposome
- Longitudinal study
- Lymphocyte
- Lymphoma
- Magnetic resonance imaging (MRI)
- Maintenance therapy
- Malignant
- Marketing Authorization Application (MAA)
- Matrix metalloproteinases (MMPs)
- Melphalan
- Metastasis
- Microvascular density (MVD)
- Mini-allogeneic transplant
- Mini-transplant
- Minimal residual disease (MRD)
- Minimal response
- Mobilization
- Monoclonal antibody
- Monoclonal gammopathy of undetermined significance (MGUS)
- Monoclonal (M) protein
- Monocyte/Macrophage
- Morphology
- MP
- Mucositis
- Mycophenolate mofetil (CellCept®)
- Myeloablation
- Myelodysplastic syndrome (MDS)
- Natural killer (NK) cell
- Near complete response (near CR)
- Nephrotoxicity
- Neuropathic Pain
- Neuropathy
- Neutropenia
- Neutrophil
- New Drug Application (NDA)
- Newly diagnosed disease
- Non-myeloablative allogenic transplant
- Nonsecretory myeloma
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Novel erythrocyte stimulating protein (NESP)
- Nuclear factor ?B (NF-?B)
- Office for Human Research Protections (OHRP)
- Orphan Drug
- Osteoblast
- Osteoclast
- Osteoclast-activating factor (OAF)
- Osteolytic lesion
- Osteonecrosis
- Osteopenia
- Osteoporosis
- Overall response rate (ORR)
- Overall survival (OS)
- Paget’s Disease
- Palifermin
- Palliative
- Palmar-plantar erythrodysesthesia (PPE)
- Pamidronate (Aredia®)
- Paraprotein
- Parathyroid hormone-related peptide (PTHrP)
- Partial response (PR)
- PCROWD study
- Performance status
- Peripheral blood
- Peripheral blood stem cell (PBSC)
- Peripheral blood stem cell (PBSC) transplant
- Peripheral edema
- Peripheral neuropathy
- Personalized medicine
- Phase 1/2 study
- Phase 1 study
- Phase 2 study
- Phase 3 study
- Phase 4 study
- Placebo
- Plasma cell
- Plasmablast
- Plasmablastic morphology
- Plasmacytoma
- Plasmapheresis
- Plateau phase
- Platelets
- Pomalyst (pomalidomide)
- Positron emission tomography (PET)
- Precision medicine
- Preclinical studies
- Precursor cell
- Prednisone
- Priority Review
- Prognosis
- Prognostic indicator
- Progression-free survival (PFS)
- Progressive disease
- PROMISE study
- Prophylactic
- Proteasome inhibitors
- Protocol
- Pulmonary embolism
- Pyrexia
- Radiation therapy (or radiotherapy)
- Radiopharmaceutical
- Randomization
- RANK L (also known as RANK Ligand)
- Red blood cell (RBC)
- Refractory disease
- Relapsed disease
- Renal Impairment
- Response Rate or Overall Response
- Revised International Staging System (R-ISS)
- Revlimid® (lenalidomide)
- RNA (ribonucleic acid)
- Salvage therapy
- Serum protein electrophoresis (SPEP)
- Smoldering multiple myeloma (SMM)
- Special Protocol Assessment (SPA)
- Stable disease (SD)
- Stage I disease
- Stage II disease
- Stage III disease
- Standard-dose chemotherapy
- Standard of care
- Standard risk disease
- Standard therapy
- Stem cell
- Stem cell transplant
- Stevens-Johnson syndrome
- Stomatitis
- Stringent complete response
- Stromal cell
- Supplemental New Drug Application (sNDA)
- Supportive care
- Synergistic
- Syngeneic stem cell transplant
- T cell
- T lymphocyte
- Tandem transplant
- Teratogenic
- Thalomid (thalidomide)
- Thrombocytopenia
- Time to progression (TTP)
- Tissue-type plasminogen activator (t-PA)
- Toxic epidermal necrosis (TEN)
- Translocation
- Treatment cycles
- Tumor-induced hypercalcemia (TIH)
- Tumor lysis syndrome
- Tumor microenvironment
- Tumor necrosis factor-alpha (TNF-a)
- Urinalysis
- Urine electrophoresis (UEP)
- VAD
- Vascular endothelial growth factor (VEGF)
- Velcade® (also known as bortezomib)
- Vertebroplasty
- Very good partial response (VGPR)
- Vincristine
- White blood cell (WBC)
- Zofran® (ondansetron)